Compare GOSS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOSS | IPHA |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 119.1M |
| IPO Year | 2018 | N/A |
| Metric | GOSS | IPHA |
|---|---|---|
| Price | $0.37 | $1.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $4.19 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 12.3M | 17.8K |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | $181.17 |
| Revenue Next Year | $147.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $1.18 |
| 52 Week High | $3.87 | $2.63 |
| Indicator | GOSS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 28.37 | 43.89 |
| Support Level | $0.33 | $1.18 |
| Resistance Level | $0.60 | $1.88 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 30.41 | 50.00 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.